The phase III FLAURA study demonstrated higher efficacy of osimertinib compared to gefitinib or erlotinib for advanced NSCLC patients harboring EGFR-sensitizing mutations, including patients with central nervous system (CNS) metastases [5, 6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.